AstraZeneca PLC
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pascal Claude Roland Soriot
- Full Time Employees
- 94,300
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge United Kingdom CB2 0AA
- IPO Date
- May 12, 1993
- CIK
- 0000901832
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company dedicated to the discovery, development, production, and worldwide commercialization of innovative prescription medicines. The company maintains a comprehensive portfolio of treatments spanning key therapeutic areas, including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, rare disease, and vaccines and immune therapies. Its innovative products serve a global patient population, reaching over 125 countries through a network of local marketing companies, distributors, and representative offices. The firm's operational focus centers on pioneering scientific breakthroughs to address significant unmet medical needs. AstraZeneca actively invests in research and development, evidenced by substantial annual expenditures aimed at advancing a robust pipeline of next-generation therapies. Recent strategic initiatives include ambitious goals for revenue growth, with an aim to launch 20 new medicines and achieve $80 billion in total revenue by 2030. AstraZeneca consistently engages in strategic partnerships and acquisitions to bolster its capabilities and pipeline. Notable collaborations include an expanded alliance with Harbour BioMed for next-generation biotherapeutics and a research agreement with CSPC Pharmaceutical Group for novel oral drug candidates. The company also recently invested $2 billion in a new Maryland manufacturing facility to establish cell therapy platforms, and its digital health solutions arm, Evinova, was launched in late 2023. Recent product advancements and approvals include Koselugo for neurofibromatosis type 1 in adults and positive Phase III results for Baxdrostat in resistant hypertension. AstraZeneca was established through the merger of Astra AB and Zeneca Group in 1999, and its headquarters are situated in Cambridge, United Kingdom.
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
FTSE 100 drops amid China banking concerns and falling oil prices
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions
AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100
5 Foreign Stocks That Could Beat The S&P 500
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do